The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 26, 2023

Filed:

Feb. 05, 2021
Applicant:

Janssen Pharmaceutica NV, Beerse, BE;

Inventors:

Mark Macielag, Lower Gwynedd, PA (US);

Raymond J. Patch, Yardley, PA (US);

Rui Zhang, Belle Mead, NJ (US);

Martin A. Case, San Diego, CA (US);

Shamina M. Rangwala, Furlong, PA (US);

James N. Leonard, Ambler, PA (US);

Raul C. Camacho, Philadelphia, PA (US);

Michael J. Hunter, Santee, CA (US);

Katharine E. D'Aquino, Perkasie, PA (US);

Wilson Edwards, Cardiff-by the-Sea, CA (US);

Ronald V. Swanson, Del Mar, CA (US);

Wenying Jian, Princeton, NJ (US);

Yue-Mei Zhang, Wellesley, MA (US);

Mark J. Wall, Lansdale, PA (US);

Ellen Chi, San Diego, CA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/575 (2006.01); A61K 47/68 (2017.01); C07K 16/24 (2006.01); A61K 9/00 (2006.01); A61K 38/17 (2006.01); A61K 38/26 (2006.01); C07K 1/06 (2006.01); C07K 1/107 (2006.01); A61K 47/64 (2017.01); A61P 3/10 (2006.01); A61K 49/00 (2006.01); C07K 1/12 (2006.01); C07K 1/18 (2006.01); C07K 5/02 (2006.01); A61K 47/60 (2017.01); A61P 3/08 (2006.01); A61P 3/00 (2006.01); A61P 3/04 (2006.01); A61P 3/06 (2006.01); A61K 38/22 (2006.01); A61K 45/06 (2006.01); C07K 16/00 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/575 (2013.01); A61K 9/0019 (2013.01); A61K 38/17 (2013.01); A61K 38/1709 (2013.01); A61K 38/22 (2013.01); A61K 38/26 (2013.01); A61K 45/06 (2013.01); A61K 47/60 (2017.08); A61K 47/64 (2017.08); A61K 47/68 (2017.08); A61K 47/6811 (2017.08); A61K 47/6845 (2017.08); A61K 47/6883 (2017.08); A61K 49/0032 (2013.01); A61K 49/0052 (2013.01); A61K 49/0056 (2013.01); A61P 3/00 (2018.01); A61P 3/04 (2018.01); A61P 3/06 (2018.01); A61P 3/08 (2018.01); A61P 3/10 (2018.01); C07K 1/061 (2013.01); C07K 1/1072 (2013.01); C07K 1/12 (2013.01); C07K 1/18 (2013.01); C07K 5/0205 (2013.01); C07K 14/57545 (2013.01); C07K 16/00 (2013.01); C07K 16/24 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/14 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/52 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/71 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/30 (2013.01);
Abstract

The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.


Find Patent Forward Citations

Loading…